<DOC>
	<DOC>NCT00059644</DOC>
	<brief_summary>Ecraprost in lipid emulsion is being developed for the treatment of Critical leg ischemia (CLI), which is the most severe form of peripheral arterial disease (PAD). This trial is designed to assess the efficacy and safety of the drug in the treatment of CLI.</brief_summary>
	<brief_title>Efficacy/Safety of Ecraprost in Lipid Emulsion for Treatment of Critical Leg Ischemia Due to Peripheral Arterial Disease</brief_title>
	<detailed_description />
	<mesh_term>Ischemia</mesh_term>
	<mesh_term>Vascular Diseases</mesh_term>
	<mesh_term>Peripheral Arterial Disease</mesh_term>
	<mesh_term>Peripheral Vascular Diseases</mesh_term>
	<criteria>Critical leg ischemia (CLI) defined as distal extremity pain at rest, or peripheral ischemic ulcer(s), with severe hemodynamic impairment as diagnosed by ankle systolic pressure, toe systolic pressure or TcPO2 The subject has exhausted all standard revascularization treatment options at this time. Subjects with a previous major amputation (at or above ankle) Subjects with end stage renal disease (ESRD) defined as significant renal dysfunction evidenced by estimated creatinine clearance of &lt; 20 cc/min, or receiving chronic hemodialysis therapy.</criteria>
	<gender>All</gender>
	<minimum_age>40 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2005</verification_date>
	<keyword>Ecraprost in lipid emulsion</keyword>
	<keyword>CLI</keyword>
	<keyword>peripheral</keyword>
	<keyword>vascular</keyword>
	<keyword>amputation</keyword>
	<keyword>Critical Limb Ischemia due to peripheral arterial disease</keyword>
</DOC>